Voluntary Announcement on Significant Progress in Research on Extracorporeal Liver Perfusion Support Therapy Using an Organ Perfusion System
Filed with HKEX · Stock code 2697 · · 3 pages · English
Summary by 6ix AI
Guangdong True Health Medical Technology Development Co. Ltd. has made a voluntary announcement regarding significant progress in its research on extracorporeal liver perfusion support therapy using an organ perfusion system. The company successfully completed preclinical trials demonstrating prolonged efficacy of its technology in supporting liver function in a model of acute liver failure. The board cautions that these trials are preclinical and do not confirm safety or efficacy in humans, urging caution for investors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Guangdong True Health Medical Technology Development Co. Ltd. on 6ix
Earlier from Guangdong True Health Medical Technology Development
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- 2026 Interim report
- Announcement of final offer price and allotment results
- List of Directors and their Roles and Functions
- Documents on Display
Follow Guangdong True Health Medical Technology Development into a list and get an email when it puts out news.
Follow Guangdong True Health Medical Technology Development